Free Trial

Roivant Sciences (ROIV) Stock Price, News & Analysis

$11.29
+0.06 (+0.53%)
(As of 05/22/2024 ET)
Today's Range
$11.18
$11.49
50-Day Range
$9.87
$11.74
52-Week Range
$8.24
$13.24
Volume
4.72 million shs
Average Volume
3.58 million shs
Market Capitalization
$9.10 billion
P/E Ratio
2.17
Dividend Yield
N/A
Price Target
$16.90

Roivant Sciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
49.7% Upside
$16.90 Price Target
Short Interest
Bearish
8.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Roivant Sciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.36) to ($1.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

482nd out of 920 stocks

Pharmaceutical Preparations Industry

218th out of 426 stocks

ROIV stock logo

About Roivant Sciences Stock (NASDAQ:ROIV)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV Stock Price History

ROIV Stock News Headlines

Roivant Sciences (ROIV) Scheduled to Post Earnings on Thursday
Roivant Sciences: Cashing In On Vants And Ventures
Sunrun (RUN) Gets a Buy from RBC Capital
Travere Therapeutics, Inc.
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)
The Analyst Landscape: 4 Takes On Roivant Sciences
See More Headlines
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
5/22/2024
Next Earnings (Confirmed)
5/30/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ROIV
Fax
N/A
Employees
904
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.90
High Stock Price Target
$23.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+49.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-1,009,030,000.00
Net Margins
3,624.14%
Pretax Margin
3,461.24%

Debt

Sales & Book Value

Annual Sales
$123.24 million
Book Value
$2.11 per share

Miscellaneous

Free Float
768,777,000
Market Cap
$9.10 billion
Optionable
Optionable
Beta
1.30
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Matthew Gline (Age 40)
    CEO & Director
    Comp: $1.77M
  • Dr. Eric Venker M.D. (Age 37)
    Pharm.D., President & COO
    Comp: $1.28M
  • Dr. Mayukh Sukhatme M.D. (Age 48)
    President, Chief Investment Officer & Director
    Comp: $1.72M
  • Mr. Richard Pulik (Age 45)
    Chief Financial Officer
  • Ms. Rakhi KumarMs. Rakhi Kumar (Age 44)
    Chief Accounting Officer
  • Dr. Huafeng Xu Ph.D.
    Chief Technology Officer
  • Mr. Jo Chen
    General Counsel
  • Ms. Kelly Graff
    Head of People
  • Ms. Marianne L. Romeo (Age 56)
    Head of Global Transactions & Risk Management
  • Mr. Alex Gasner
    Executive Vice President of Roivant Health

ROIV Stock Analysis - Frequently Asked Questions

Should I buy or sell Roivant Sciences stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ROIV shares.
View ROIV analyst ratings
or view top-rated stocks.

What is Roivant Sciences' stock price target for 2024?

10 brokerages have issued 1 year target prices for Roivant Sciences' shares. Their ROIV share price targets range from $12.00 to $23.00. On average, they expect the company's stock price to reach $16.90 in the next year. This suggests a possible upside of 49.7% from the stock's current price.
View analysts price targets for ROIV
or view top-rated stocks among Wall Street analysts.

How have ROIV shares performed in 2024?

Roivant Sciences' stock was trading at $11.23 at the start of the year. Since then, ROIV shares have increased by 0.5% and is now trading at $11.29.
View the best growth stocks for 2024 here
.

When is Roivant Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 30th 2024.
View our ROIV earnings forecast
.

How can I listen to Roivant Sciences' earnings call?

Roivant Sciences will be holding an earnings conference call on Thursday, May 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Roivant Sciences' earnings last quarter?

Roivant Sciences Ltd. (NASDAQ:ROIV) announced its earnings results on Monday, August, 14th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.10. The business earned $21.60 million during the quarter, compared to analysts' expectations of $24.49 million. Roivant Sciences had a negative trailing twelve-month return on equity of 33.38% and a net margin of 3,624.14%. The firm's revenue was up 402.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.48) earnings per share.

Who are Roivant Sciences' major shareholders?

Roivant Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Patient Square Capital LP (1.52%), Vanguard Group Inc. (1.01%), Baker BROS. Advisors LP (0.92%), Whitefort Capital Management LP (0.30%), Penn Davis Mcfarland Inc. (0.20%) and Tyro Capital Management LLC (0.19%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy.
View institutional ownership trends
.

How do I buy shares of Roivant Sciences?

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ROIV) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners